Literature DB >> 19043735

The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children.

Tulay Guran1, Serap Turan, Abdullah Bereket, Teoman Akcay, Goksenin Unluguzel, Firdevs Bas, Hulya Gunoz, Nurcin Saka, Ruveyde Bundak, Feyza Darendeliler, Pinar Isguven, Metin Yildiz, Erdal Adal, Sevil Sarikaya, Leyla Akin Baygin, Nihal Memioglu, Hasan Onal, Oya Ercan, Goncagul Haklar.   

Abstract

INTRODUCTION: In this study, we have investigated the role of leptin, soluble leptin receptor(sOb-R), resistin, and insulin secretory dynamics in the development of hypothalamic obesity.
MATERIALS AND METHODS: Children who had hypothalamo-pituitary tumor were divided into two groups. First group included obese-overweight (hypothalamic obese = HOB group, n = 23) and second group included non-obese children (hypothalamic non-obese = HNOB group, n = 16). Exogenously obese-overweight children (OB group, n = 22) were included as controls. Basal and second-hour serum glucose and insulin in oral glucose tolerance test (OGTT), basal serum leptin, sOb-R, resistin levels, and homeostasis model assessment (HOMA) indexes were compared between the groups.
RESULTS: Age, sex, and pubertal status were similar in study groups. Median and interquartile ranges of body mass index (BMI) z scores were similar in HOB and OB groups (2.0 (1.5-2.1) and 2.1 (1.8-2.3), respectively). Serum leptin levels corrected for BMI were highest and total leptin/sOb-R ratios (free leptin index (FLI)) tended to be higher in HOB than HNOB and OB groups, indicating leptin resistance (leptin/BMI, 4.0 (1.6-5.2), 1.5 (0.8-3.1), and 2.5 (1.8-3.5); FLI, 2.0 (0.8-3.5), 0.6 (0.3-1.2), and 1.5 (1-2.3) in HOB, HNOB, and OB groups; respectively). Serum resistin levels were similar in groups (2.6 (1.9-3.1), 2.8 (1.7-3.4), and 3.0 (2.2-3.5) ng/ml in HOB, HNOB, and OB groups, respectively). Basal serum glucose, basal and second-hour insulin levels in OGTT, and HOMA index were higher in OB group than the HOB and HNOB groups, indicating insulin resistance in simple obesity; however, increment of insulin to same glycemic load in OGTT was highest in the HOB group indicating insulin dysregulation (p < 0.05).
CONCLUSION: Hypothalamic obesity seems to be related to both dysregulated afferent (leptin) and efferent (insulin) neural outputs through the autonomic nervous system resulting in energy storage as fat.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043735     DOI: 10.1007/s00431-008-0876-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  30 in total

1.  Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin.

Authors:  Naoya Igaki; Maki Tanaka; Takeo Goto
Journal:  Intern Med       Date:  2005-08       Impact factor: 1.271

2.  Hypothalamic resistin induces hepatic insulin resistance.

Authors:  Evan D Muse; Tony K T Lam; Philipp E Scherer; Luciano Rossetti
Journal:  J Clin Invest       Date:  2007-05-24       Impact factor: 14.808

3.  Serum resistin is not associated with obesity or insulin resistance in humans.

Authors:  N Iqbal; P Seshadri; L Stern; J Loh; S Kundu; T Jafar; F F Samaha
Journal:  Eur Rev Med Pharmacol Sci       Date:  2005 May-Jun       Impact factor: 3.507

4.  Increased resistin gene and protein expression in human abdominal adipose tissue.

Authors:  Philip G McTernan; Claire L McTernan; Rajkumar Chetty; Keely Jenner; Ffolliott M Fisher; Michelle N Lauer; John Crocker; Anthony H Barnett; Sudhesh Kumar
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

5.  Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients.

Authors:  Hermann L Müller; Sarah Müller-Stöver; Ursel Gebhardt; Reinhard Kolb; Niels Sörensen; Georg Handwerker
Journal:  J Pediatr Endocrinol Metab       Date:  2006-04       Impact factor: 1.634

6.  Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial.

Authors:  Robert H Lustig; Pamela S Hinds; Karen Ringwald-Smith; Robbin K Christensen; Sue C Kaste; Randi E Schreiber; Shesh N Rai; Shelly Y Lensing; Shengjie Wu; Xiaoping Xiong
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

7.  Features of the metabolic syndrome after childhood craniopharyngioma.

Authors:  S Srinivasan; G D Ogle; S P Garnett; J N Briody; J W Lee; C T Cowell
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

8.  Soluble leptin receptor represents the main leptin binding activity in human blood.

Authors:  A Lammert; W Kiess; A Bottner; A Glasow; J Kratzsch
Journal:  Biochem Biophys Res Commun       Date:  2001-05-18       Impact factor: 3.575

9.  The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women.

Authors:  K Anderlová; J Kremen; R Dolezalová; J Housová; D Haluzíková; M Kunesová; M Haluzík
Journal:  Physiol Res       Date:  2005-08-05       Impact factor: 1.881

10.  Free and total leptin serum levels and soluble leptin receptors levels in two models of genetic obesity: the Prader-Willi and the Down syndromes.

Authors:  Caterina Proto; Daniela Romualdi; Rosa Maria Cento; Corrado Romano; Giuseppe Campagna; Antonio Lanzone
Journal:  Metabolism       Date:  2007-08       Impact factor: 8.694

View more
  8 in total

Review 1.  Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application.

Authors:  Christos Bikis; Theodora Tzanavari; Krystallenia I Alexandraki; Stamatios Theocharis
Journal:  Horm Cancer       Date:  2018-02-20       Impact factor: 3.869

Review 2.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

3.  A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.

Authors:  Jefferson P Lomenick; Maciej S Buchowski; Ashley H Shoemaker
Journal:  Obesity (Silver Spring)       Date:  2016-05-02       Impact factor: 5.002

4.  Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience.

Authors:  Michal Cohen; Sharon Guger; Jill Hamilton
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-28       Impact factor: 5.555

Review 5.  Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention.

Authors:  Christian L Roth
Journal:  J Clin Med       Date:  2015-09-09       Impact factor: 4.241

Review 6.  Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents.

Authors:  Ja Hye Kim; Jin-Ho Choi
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-12-31

7.  Cardiac autonomic dysfunction is associated with hypothalamic damage in patients with childhood-onset craniopharyngioma.

Authors:  Hae Woon Jung; Hwa Young Kim; Ji Young Kim; Jung-Eun Cheon; In-One Kim; Seung-Ki Kim; Choong Ho Shin; Sei Won Yang; Young Ah Lee
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

8.  Transition From Diencephalic Syndrome to Hypothalamic Obesity in Children With Suprasellar Low Grade Glioma: A Case Series.

Authors:  Ichelle M A A van Roessel; Antoinette Y N Schouten-van Meeteren; Lisethe Meijer; Eelco W Hoving; Boudewijn Bakker; Hanneke M van Santen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.